Gilead buying another NASH program for up to $470m
This article was originally published in Scrip
Gilead Sciences has two market-leading drugs to treat hepatitis C and now the company is expanding its liver disease empire with the acquisition of small molecules for the treatment of non-alcoholic steatohepatitis (NASH) from Phenex Pharmaceuticals.
You may also be interested in...
With hepatitis C wrapped up, NASH is becoming the focus of liver disease R&D. Gilead, which has a number of NASH programs, has paid Phenex $100m for clinical progress with an in-licensed candidate for NASH and other liver diseases.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.